GAITHERSBURG, Md., July 12, 2021 /PRNewswire/ -- MaxCyte, Inc.,
(LSE: MXCT) (LSE: MXCN), a leading provider of platform
technologies for cell engineering ("MaxCyte" or the
"Company"), today announced the public filing of a
registration statement on Form S-1 with the Securities and Exchange
Commission (the "SEC") for a proposed dual-listing and public
offering of shares of common stock on the Nasdaq Stock Market (the
"offering"). The registration statement included a proposed change
to the board of directors as well as unaudited financial
information which is detailed below.
Financial information in the Form S-1 registration
statement
The Company's Form S-1 registration statement contains unaudited
consolidated financial statements for the period from 1 January 2021 to 31 March
2021 prepared in accordance with generally accepted
accounting principles in the United
States ("U.S. GAAP"). Such consolidated financial
statements, as extracted from the Form S-1 registration statement,
are attached to this announcement.
PDF -
https://mma.prnewswire.com/media/1571440/MaxCyte_Inc_PDF.pdf
Financial and operational highlights for the period include:
- Revenue growth in the first quarter of 2021 excluding revenue
from milestones was 30% compared to the first quarter of 2020.
Revenue growth in Q1 2021 including milestone revenues was 13%
compared to the first quarter of 2020 ($6.5m in Q1 2021 and $5.7m in Q1 2020)
- Incurred CARMA-related operating expenses of $3.9 million
during the first quarter. The Company concluded all material
CARMA activities in the first half of 2021, as planned, principally
within Q1
- Completed private placement in February 2021 of
$55.3m with a mix of new and
existing crossover investors led by D1 Capital Partners, Funds
and accounts advised by T. Rowe Price Associates,
Inc., ArrowMark Partners, Baron Capital Group and
First Light Asset Management with Casdin
Capital and Sofinnova Partners
- Signed one new strategic platform licence during the quarter,
with Myeloid Therapeutics, Inc., thereby enabling Myeloid to
advance pipeline programs for engineered cell therapies targeting
solid tumors, T cell lymphoma, and glioblastoma
Upon the offering, the Company will commence disclosure of
quarterly financial statements in compliance with SEC filing
requirements and continue to prepare the financial statements
included in its annual and half-yearly reports as required by the
AIM Rules for Companies published by the London Stock Exchange.
Change to Board of Directors
Ron Holtz has served as MaxCyte's
Senior Vice-President and Chief Accounting Officer ("CAO") since
September 2020 and had previously
served as the Company's Chief Financial Officer ("CFO") from 2005
to September 2020. Mr. Holtz has also
served on MaxCyte's board of directors since 2016. In line with
Nasdaq best practices to not have the CFO nor CAO on a Company's
board, Mr. Holtz has resigned from our board of directors. Mr.
Holtz will continue to serve the company in the CAO role.
This press release is being made pursuant to, and in accordance
with Rule 135 under the Securities Act of 1933, as amended (the
"Securities Act"). This press release does not constitute an offer
to sell or the solicitation of an offer to buy securities, and
shall not constitute an offer, solicitation or sale in any
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of that jurisdiction. Any offers, solicitations or
offers to buy, or any sales of securities will be made in
accordance with the registration requirements of the Securities
Act.
About MaxCyte
MaxCyte is a leading commercial cell-engineering company focused
on providing enabling platform technologies to advance innovative
cell-based research as well as next-generation cell therapeutic
discovery, development and commercialization. MaxCyte's existing
customer base ranges from large biopharmaceutical companies —
including all of the top 10, and 20 of the top 25, pharmaceutical
companies based on 2020 global revenue — to hundreds of
biotechnology companies and academic centers focused on
translational research. MaxCyte has granted 13 strategic platform
licenses to commercial cell therapy developers covering more than
75 programs under clinical licenses that are part of the strategic
platform licenses. MaxCyte was founded in 1998 and is headquartered
in Gaithersburg, Maryland, US.
MaxCyte Contacts:
MaxCyte Inc.
Doug Doerfler, Chief Executive
Officer
Amanda Murphy, Chief Financial
Officer
+1-301-944-1660
Nominated Adviser and Joint Corporate Broker
Panmure Gordon
Emma Earl /
Freddy Crossley
Corporate Broking
Rupert Dearden
+44 (0)20 7886 2500
Joint Corporate Broker
Numis Securities Limited
James
Black / Duncan Monteith /
Matthew O'Dowd
+44 (0)20 7260 1000
Joint Corporate Broker
Stifel Nicolaus Europe Limited
Healthcare Investment Banking
Nicholas Moore / Ben Maddison / Samira Essebiyea
Corporate Broking
Nick Adams
+44 (0)20 7710 7600
Financial PR Adviser
Consilium Strategic Communications
Mary-Jane Elliott
Chris Welsh
+44 (0)203 709 5700
maxcyte@consilium-omms.com
US IR Adviser
Gilmartin Group
David
Deuchler, CFA
david@gilmartinir.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/financial-information-in-the-form-s-1-registration-statement-and-change-to-board-of-directors-301331151.html
SOURCE MaxCyte, Inc.